Published in BMC Cancer on November 11, 2011
Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes. Oncotarget (2015) 1.13
Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer. Br J Cancer (2012) 0.82
Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene (2015) 0.81
Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer (2014) 0.76
Structural insights into FRS2α PTB domain recognition by neurotrophin receptor TrkB. Proteins (2014) 0.75
Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells. Oncotarget (2017) 0.75
MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget (2016) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell (1997) 4.43
Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A (2001) 2.28
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer (2004) 1.86
The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation. J Biol Chem (1999) 1.56
Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther (2003) 1.56
Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins. J Biol Chem (1998) 1.54
Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res (1997) 1.48
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther (2009) 1.33
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol (2001) 1.29
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res (2003) 1.19
Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene (1999) 1.15
The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development. Mol Cell Biol (2005) 1.12
FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Lett (2004) 1.10
Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate (2002) 1.10
Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene (1998) 1.06
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol (2010) 1.04
Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst (2001) 1.03
FGF8 isoform b expression in human prostate cancer. Br J Cancer (2003) 1.01
Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol (2004) 0.97
FRS2beta, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding. Oncogene (2010) 0.95
Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer (2010) 0.94
Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest (2001) 0.94
MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol (2001) 0.89
FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res (2009) 0.88
Laser-capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer. Methods Mol Biol (2011) 0.86
FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer (1999) 0.86
The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins. Endocrinology (2003) 0.85
Trk receptor binding and neurotrophin/fibroblast growth factor (FGF)-dependent activation of the FGF receptor substrate (FRS)-3. Biochim Biophys Acta (2006) 0.84
Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. Oncogene (2006) 0.84
Fibroblast growth factor receptor substrate 2 participates in vascular endothelial growth factor-induced signaling. FASEB J (2002) 0.81
The fibroblast growth factor receptor substrate 3 adapter is a developmentally regulated microtubule-associated protein expressed in migrating and differentiated neurons. J Neurochem (2009) 0.79
Cell- and receptor isotype-specific phosphorylation of SNT1 by fibroblast growth factor receptor tyrosine kinases. In Vitro Cell Dev Biol Anim (2002) 0.79
Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells. Int J Oncol (2006) 0.76
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 1.56
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation. BJU Int (2011) 1.05
Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. BJU Int (2014) 1.04
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol (2010) 1.04
The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99
Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int (2008) 0.99
Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PLoS One (2013) 0.98
Prostate cancer: performance characteristics of combined T₂W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. Eur Radiol (2014) 0.95
Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer (2010) 0.94
Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer. AJR Am J Roentgenol (2014) 0.91
Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int J Clin Exp Pathol (2009) 0.91
In vivo detection of MRI-PARACEST agents in mouse brain tumors at 9.4 T. Magn Reson Med (2011) 0.89
Laser-capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer. Methods Mol Biol (2011) 0.86
Cyclic phosphatidic acid elicits neurotrophin-like actions in embryonic hippocampal neurons. J Neurochem (2003) 0.85
The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol (2012) 0.84
Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson Med (2010) 0.80
Diagnostic accuracy of preoperative computed tomography used alone to detect lymph-node involvement at radical nephrectomy. Scand J Urol (2015) 0.79
Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer (2014) 0.76